HOTLINE: Effective November 15, 2021

New Test **3004102** **Marfan Syndrome (FBN1) Sequencing and Deletion/Duplication** **FBN1 NGS**

Patient History for Marfan Syndrome Testing

Additional Technical Information

Methodology: Massively Parallel Sequencing/Multiplex Ligation-dependent Probe Amplification
Performed: Varies
Reported: 3-6 weeks

Specimen Required: Collect: Lavender (EDTA) or Yellow (ACD Solution A or B).
Specimen Preparation: Transport 3 mL whole blood. (Min: 3 mL)
Storage/Transport Temperature: Refrigerated
Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens
Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval: By report

Interpretive Data:
Refer to report

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note: Gene Tested: FBN1

CPT Code(s): 81408, 81479

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.